207 related articles for article (PubMed ID: 28621004)
21. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
[TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Saba CF; Thamm DH; Vail DM
J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
[TBL] [Abstract][Full Text] [Related]
23. Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000-2015).
Marlowe KW; Robat CS; Clarke DM; Taylor A; Touret M; Husbands BD; Vail DM
Vet Comp Oncol; 2018 Dec; 16(4):658-663. PubMed ID: 30246460
[TBL] [Abstract][Full Text] [Related]
24. Outcome in dogs with curative-intent treatment of localized primary pulmonary histiocytic sarcoma.
Murray CA; Willcox JL; De Mello Souza CH; Husbands B; Cook MR; Clifford C; Leeper H; Pellin M; Richardson D; Herrera CL; Krick E; McMillan S; Al-Nadaf S; Skorupski KA
Vet Comp Oncol; 2022 Jun; 20(2):458-464. PubMed ID: 34878710
[TBL] [Abstract][Full Text] [Related]
25. Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.
Treggiari E; Cossu G; Valenti P; Taylor A
Vet Comp Oncol; 2022 Sep; 20(3):577-586. PubMed ID: 35249267
[TBL] [Abstract][Full Text] [Related]
26. Outcome comparison between radiation therapy and surgery as primary treatment for dogs with periarticular histiocytic sarcoma: An Italian Society of Veterinary Oncology study.
Marconato L; Sabattini S; Buchholz J; Polton G; Finotello R; Martano M; Willman M; Massari F; Agnoli C; Gedon J; Cancedda S; Campigli M; Rohrer Bley C
Vet Comp Oncol; 2020 Dec; 18(4):778-786. PubMed ID: 32396662
[TBL] [Abstract][Full Text] [Related]
27. Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma.
Elliott JW; Cripps P; Marrington AM; Grant IA; Blackwood L
Vet Comp Oncol; 2013 Sep; 11(3):185-98. PubMed ID: 22372620
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of the two-base insertion mutation in the TP53 gene in canine histiocytic sarcoma.
Asada H; Tomiyasu H; Okada K; Chambers JK; Goto-Koshino Y; Uchida K; Kagawa Y; Ohno K; Tsujimoto H
Res Vet Sci; 2019 Jun; 124():57-60. PubMed ID: 30852355
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan.
Takahashi M; Tomiyasu H; Hotta E; Asada H; Fukushima K; Kanemoto H; Fujino Y; Ohno K; Uchida K; Nakayama H; Tsujimoto H
J Vet Med Sci; 2014 May; 76(5):661-6. PubMed ID: 24441652
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
Saba CF; Hafeman SD; Vail DM; Thamm DH
J Vet Intern Med; 2009; 23(5):1058-63. PubMed ID: 19678892
[TBL] [Abstract][Full Text] [Related]
31. Doxorubicin for treatment of histiocytic sarcoma in dogs: 31 cases (2003-2017).
Doka RM; Suter SE; Mastromauro ML; Bennett AL; Hess PR
J Am Vet Med Assoc; 2022 Sep; 260(14):1827-1833. PubMed ID: 36054007
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis inhibitor of macrophage (AIM) reduces cell number in canine histiocytic sarcoma cell lines.
Uchida M; Saeki K; Maeda S; Tamahara S; Yonezawa T; Matsuki N
J Vet Med Sci; 2016 Oct; 78(9):1515-1520. PubMed ID: 27246397
[TBL] [Abstract][Full Text] [Related]
33. A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.
Takada M; Parys M; Gregory-Bryson E; Vilar Saavedra P; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2018 Mar; 18(1):237. PubMed ID: 29490634
[TBL] [Abstract][Full Text] [Related]
34. Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.
Takada M; Smyth LA; Hix JM; Corner SM; Kiupel M; Yuzbasiyan-Gurkan V
Comp Med; 2019 Feb; 69(1):22-28. PubMed ID: 30717820
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.
Hosoya K; Kisseberth WC; Alvarez FJ; Lara-Garcia A; Beamer G; Stromberg PC; Couto CG
J Am Anim Hosp Assoc; 2009; 45(1):14-8. PubMed ID: 19122059
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological characteristics of histiocytic sarcoma affecting the central nervous system in dogs.
Toyoda I; Vernau W; Sturges BK; Vernau KM; Rossmeisl J; Zimmerman K; Crowe CM; Woolard K; Giuffrida M; Higgins RJ; Dickinson PJ
J Vet Intern Med; 2020 Mar; 34(2):828-837. PubMed ID: 31919895
[TBL] [Abstract][Full Text] [Related]
37. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-2004).
Kim SE; Liptak JM; Gall TT; Monteith GJ; Woods JP
J Am Vet Med Assoc; 2007 Nov; 231(10):1550-7. PubMed ID: 18021000
[TBL] [Abstract][Full Text] [Related]
38. A 2-base insertion in exon 5 is a common mutation of the TP53 gene in dogs with histiocytic sarcoma.
Asada H; Tsuboi M; Chambers JK; Uchida K; Tomiyasu H; Goto-Koshino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2017 Oct; 79(10):1721-1726. PubMed ID: 28867679
[TBL] [Abstract][Full Text] [Related]
39. Impact of palliative-intent radiotherapy with or without chemotherapy on lameness in flat coat retrievers with localised periarticular histiocytic sarcoma - a retrospective cohort, single institution study.
Odatzoglou P; Kearns T; Pittaway C; Dobson JM
Vet Comp Oncol; 2024 Mar; 22(1):22-29. PubMed ID: 37935625
[TBL] [Abstract][Full Text] [Related]
40. Metronomic administration of lomustine following palliative radiation therapy for appendicular osteosarcoma in dogs.
Duffy ME; Anderson CL; Choy K; Fidel JL
Can Vet J; 2018 Feb; 59(2):136-142. PubMed ID: 29386671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
